File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Systemic administration of naked DNA encoding interleukin 12 for the treatment of human papillomavirus DNA-positive tumor

TitleSystemic administration of naked DNA encoding interleukin 12 for the treatment of human papillomavirus DNA-positive tumor
Authors
Issue Date2002
Citation
Human Gene Therapy, 2002, v. 13 n. 2, p. 177-185 How to Cite?
AbstractInterleukin 12 (IL-12) is one of the most effective and promising cytokines for cancer therapy. Its therapeutic effects have been demonstrated in a variety of tumors in animal models when it is administrated locally or systemically. We describe here a systemic delivery of naked murine IL-12 (mIL-12) gene in vivo. Dose-dependent systemic production of mIL-12, with a serum level up to approximately 20 μg/ml, was observed 24 hr after systemic gene delivery. The apparent half-life in the circulation was about 5 hr. The result of a bioactivity assay (in vitro interferon γ [IFN-γ] release) indicated that the gene product in mice was as active as the purified recombinant murine IL-12 protein (rmIL-12). The circulating mIL-12 activated natural killer cells and stimulated IFN-γ production in vivo. A single administration of mIL-12 gene resulted in prominent regression of established subcutaneous tumor in a human papillomavirus (HPV) DNA-positive tumor model (TC-1) in C57BL/6J mice. The antitumor effect of the single gene dose was comparable to repeated intraperitoneal administration of rmIL-12 (0.5 μg/day for consecutive 5 days). This systemic gene delivery is simple, economical, and highly efficient for the production of large amounts of cytokine in vivo. With this gene delivery method, we have demonstrated the therapeutic potential of IL-12 for the treatment of HPV DNA-positive tumor and the usefulness of the systemic gene delivery for assessing the therapeutic effect of a candidate gene.
Persistent Identifierhttp://hdl.handle.net/10722/194125
ISSN
2015 Impact Factor: 4.062
2015 SCImago Journal Rankings: 1.687
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLui, VWY-
dc.contributor.authorHe, Y-
dc.contributor.authorFalo, L-
dc.contributor.authorHuang, L-
dc.date.accessioned2014-01-30T03:32:12Z-
dc.date.available2014-01-30T03:32:12Z-
dc.date.issued2002-
dc.identifier.citationHuman Gene Therapy, 2002, v. 13 n. 2, p. 177-185-
dc.identifier.issn1043-0342-
dc.identifier.urihttp://hdl.handle.net/10722/194125-
dc.description.abstractInterleukin 12 (IL-12) is one of the most effective and promising cytokines for cancer therapy. Its therapeutic effects have been demonstrated in a variety of tumors in animal models when it is administrated locally or systemically. We describe here a systemic delivery of naked murine IL-12 (mIL-12) gene in vivo. Dose-dependent systemic production of mIL-12, with a serum level up to approximately 20 μg/ml, was observed 24 hr after systemic gene delivery. The apparent half-life in the circulation was about 5 hr. The result of a bioactivity assay (in vitro interferon γ [IFN-γ] release) indicated that the gene product in mice was as active as the purified recombinant murine IL-12 protein (rmIL-12). The circulating mIL-12 activated natural killer cells and stimulated IFN-γ production in vivo. A single administration of mIL-12 gene resulted in prominent regression of established subcutaneous tumor in a human papillomavirus (HPV) DNA-positive tumor model (TC-1) in C57BL/6J mice. The antitumor effect of the single gene dose was comparable to repeated intraperitoneal administration of rmIL-12 (0.5 μg/day for consecutive 5 days). This systemic gene delivery is simple, economical, and highly efficient for the production of large amounts of cytokine in vivo. With this gene delivery method, we have demonstrated the therapeutic potential of IL-12 for the treatment of HPV DNA-positive tumor and the usefulness of the systemic gene delivery for assessing the therapeutic effect of a candidate gene.-
dc.languageeng-
dc.relation.ispartofHuman Gene Therapy-
dc.titleSystemic administration of naked DNA encoding interleukin 12 for the treatment of human papillomavirus DNA-positive tumor-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1089/10430340252769716-
dc.identifier.pmid11812275-
dc.identifier.scopuseid_2-s2.0-0036173196-
dc.identifier.volume13-
dc.identifier.issue2-
dc.identifier.spage177-
dc.identifier.epage185-
dc.identifier.isiWOS:000173499600001-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats